Startup profile · funding coverage
Precision Neuroscience funding, valuation and investors
A minimally invasive cortical interface for people with paralysis.
Keep track of Precision Neuroscience
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series D
$250M · September 24, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$250M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · New York, New York
Investors in latest funding
Lead: Pershing Square Inc. , Ackman Oxman Institute , Undisclosed life-sciences investment fund
Other: B Capital , ARK Invest , Mubadala Capital
Overview
Brain-computer interface company developing a thin, minimally invasive cortical electrode array intended to restore communication and computer control.
Why Precision Neuroscience is interesting
Precision is moving brain-computer interfaces toward broader clinical use with an FDA-cleared electrode array and experience from more than 100 patient procedures.
Funding history (newest first)
Series D
2026-09-24 $250M- Pershing Square Inc. (lead)
- Ackman Oxman Institute (lead)
- Undisclosed life-sciences investment fund (lead)
- B Capital (participant)
- ARK Invest (participant)
- Mubadala Capital (participant)
Market / IPO context
Editorial / static context — not a live quote.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.